Tailoring Cell Culture Media for Successful Cell Therapy Development

Cell culture media is critical for developing cell therapies, serving as the foundation for growing and maintaining therapeutic cells. This article explores recent innovations in cell culture media, the importance of optimizing media formulations to support cell health and performance, and how to meet the needs of different cell types used in therapies. It also addresses challenges in large-scale manufacturing, cell transport, and regulatory compliance.

The evolution of cell culture media

Cell culture media typically contain a complex mixture of amino acids, vitamins, inorganic salts, growth factors, and other components. Historically, animal serum was widely used to provide nutrients and osmolarity to support cell growth.

“Cell culture media formulation has evolved over the years from using natural components as protein source supplements, such as animal serum, to chemical-based synthetic formulation,” says Fang Tian, Ph.D., Director of Biological Content at ATCC. “Xeno-free and chemically defined media, compared to classical media, help reduce the batch-to-batch variability and the risk of immunogenicity. Simply put, it is a safer and more reliable media type that facilitates the development and manufacturing of cell therapies.”

Sreethu Sankar, Product Manager at Proteintech, highlights further innovations: " In addition to serum-free and chemically defined media, human cell-derived growth factors are at the forefront of advancements. Additionally, modular media formulation systems now allow for custom formulations that meet the specific needs of various cell types while adhering to safety and regulatory requirements. These systems enable manufacturers to fine-tune nutrient concentrations, growth factors, and other components to maintain cell quality without compromising on compliance.”

Human cell-derived growth factors

Growth factors are crucial components that drive cell expansion and differentiation. Traditionally produced using bacterial systems, these growth factors lacked the post-translational modifications necessary for their full bioactivity and stability.

“To ensure the highest bioactivity and stability of growth factors in cell culture, sourcing them from human cells is essential, as they can provide the necessary post-translational modifications,” explains Sankar. “This approach yields more reliable and effective outcomes in cell culture applications. Thus, Proteintech provides HumanKine growth factors, entirely derived from human cells in compliance with strict GMP guidelines, for use in cell therapy manufacturing applications.”

Optimizing cell culture media for different types of cell therapies

"Cell culture media optimization is vital for successful cell therapy as it directly influences cell growth, viability, phenotype, and function," says Mark Koza, Business Director of Cell Culture Media at Corning Life Sciences. "A well-formulated and optimized media will support robust cell growth and maintain cell health, leading to success in cell therapy applications." Critical factors for media optimization include nutrient composition, growth factors, pH, osmolarity, temperature, and CO₂ concentration. “Several approaches, such as high-throughput screening, advanced analytical tools, like metabolomics and proteomics, as well as computational models, can help us better identify the optimal media formulations for specific cell types,” adds Koza.

Cell culture media options for cell therapies range from custom-developed formulations to commercial off-the-shelf media products. Each media component can significantly affect cell growth, transfection efficiency, and other bio-functional attributes that influence therapeutic efficacy. “As the industry shifts toward animal-free media for cell therapy, optimizing the precise concentrations of every component in the media becomes even more critical for maintaining cell health and functionality,” notes Sankar.

CAR-T therapy, one of the most rapidly growing cell therapy modalities, requires carefully optimized media for cell activation, proliferation, and preparation to be functionally ready to provide anti-tumor responses once administered to patients. “Specific amino acids, such as leucine, glutamine, arginine, alanine, serine, and tryptophan, are critical for T-cell activation and proliferation,” explains Tian. “Leucine and glutamine regulate T-cell differentiation, while extracellular alanine plays a vital role in their activation and proliferation.”

“The concentrations of these amino acids vary across commercially available media from different vendors,” adds Tian. “Additionally, primary T cells vary from donor to donor, and the different ex vivo activation methods can also impact amino acid uptake. Therefore, careful screening and optimization are crucial to finding the media that best supports the therapeutic potential of these cells.”

Optimizing cell culture media for large-scale manufacturing

Transitioning from small-scale laboratory environments to large-scale manufacturing presents several challenges. “Optimizing cell culture media for therapeutic cells in large-scale manufacturing requires overcoming issues like ensuring scalability, as media conditions that work in small labs may not translate to larger systems,” says Sankar. “Maintaining cell phenotype and functionality is complex due to the dynamic needs of different cell types throughout their growth and differentiation.”

Another significant hurdle is variability in media components, particularly when using undefined ingredients like serum, which can lead to inconsistent results. Additionally, nutrient depletion and waste accumulation further complicate large-scale processes.

“Meeting regulatory requirements for GMP compliance adds another layer of complexity, limiting formulation options,” Sankar adds. “Sourcing costly raw materials at scale introduces economic and logistical challenges. On top of that, the bioreactor environment must be carefully controlled to prevent physical stress that could compromise cell behavior and therapeutic efficacy.”

Ensuring the stability and viability of cells during transport

To maintain cell viability and stability during transport, best practices include thorough cell model development and characterization, robust quality control (QC) tests for each production batch, tightly controlled cell cryopreservation processes, long-term cold chain storage conditions, and efficient, secure packing and shipping.

“In cell therapy, precise control during cell freezing and storage is critical but challenging,” says Tian. “For example, post-thaw viability of cryopreserved CAR-T cells or stem cells can be significantly impacted by the cryopreservation media formulation. Classical cryopreservation media contain dimethyl sulfoxide (DMSO), a critical cryoprotectant, which can be toxic to cells and cause adverse reactions in patients. Serum derivatives in classical cryopreservation media may also cause unintended immune reactions in patients.”

Tian adds that research is ongoing to develop DMSO-free and animal by-product-free cryopreservation media that could offer safer and more effective solutions for cell therapies. "For cell therapy success, the media strategies should encompass both cell culture and cell cryopreservation media," Tian emphasizes.

Addressing safety and regulatory concerns in media formulation

Finally, the choice of cell culture media and its components must align with safety and regulatory requirements for cell therapies. "Using xeno-free and serum-free media reduces the risk of animal-derived contaminants and potential immunogenic components, addressing safety concerns," says Koza. "Chemically defined media, where every ingredient is known, quantifiable, and controllable, help meet the stringent regulatory requirements for reproducibility and consistency.” Additionally, using GMP-grade components, regulatory-compliant raw materials, quality controls, and risk assessment strategies ensures that quality and safety standards are met.

Koza concludes, “Close collaborations between researchers, cell culture media suppliers, and regulatory bodies are crucial for successful large-scale cell therapy production.”